Positive update on partner deals
Destiny have announced a trading update that includes a bolus of progress on the partnering of its two Phase 3-ready products. A transaction for NTCD-M3 has reached the heads of terms and exclusivity stages, while on XF-73 the partnering process is underway and aiming for a 2023 deal.Destiny have agreed heads of terms and entered into exclusivity with a US pharmaceutical company for the funding of the Phase 3 program and commercialization of its lead Phase 3 product, the non-toxigenic Clostridioides difficile strain M3 (NTCD-M3) for the prevention of C.difficile infections. The transaction is expected to be announced in early 2023.
The update also included the detail that an active partnering campaign is now ongoing for Destiny’s second Phase 3-ready product XF-73 nasal gel for the prevention of post-surgical staphylococcal infections. With early discussions underway, we have not changed our model that anticipates a transaction in 2023.
Our Fair Value for Destiny Pharma remains unchanged at £251.2m or 345p per share.
Destiny Pharma is engaged in the discovery, development and commercialization of antimicrobials that have properties to improve outcomes for patients and the delivery of medical care into the future.
Equity Development enables companies to become better understood and supported by investors. Since our launch in 1996 we have consistently focused on helping our clients improve their communication and relationships with both existing and potential shareholders. Our clients have come from a wide variety of sectors and domiciles, are both private and quoted and range in size from micro-cap to $multi-billions. We offer free access to company research notes written by experienced analysts. These notes include detailed forecasts, financial models and a fair value. We host regular Private Investor Forums at which investors have the opportunity to hear company directors present, and to ask questions. These are free to attend. We broadcast live Webinars with company management that include active Q&A. We also make the recordings available online. We arrange face to face meetings between private investors and company management. We are active users of Twitter, commenting daily on company news, share price moves, Directors’ Dealings, Equity Development Research Notes & Events.
Unfortunately, this report is not available for the investor type or country you selected.
Browse all ResearchPool reportsReport is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.